Good science deserves disciplined capital.
Investing in deep technology begins by understanding what a company has actually proved. The hard part is deciding what remains to be done, how much it should cost, whether the team can do it, and whether the result will create a business worth owning.
Six questions we return to.
These are questions we want to return to, including when the science is compelling and the market is enthusiastic.
- 1
Consequence
If the company succeeds, does the result solve a problem that will still matter in ten or twenty years?
- 2
Depth
What is genuinely difficult to reproduce: a biological mechanism, technical capability, data asset, manufacturing process or operating advantage?
- 3
Proof
What is known today? What result would change our view? What is the next decisive experiment or commercial milestone?
- 4
Commercial reality
Who benefits, who pays, what must be adopted, and why will the economics work outside a presentation?
- 5
Capital discipline
How much is required to reach the next useful answer? What happens to ownership, dilution, follow-on capital and the eventual return if the process takes longer?
- 6
Integrity
Are the science, governance, incentives and consequences of deployment defensible?
The work between conviction and commitment.
Reconstruct the actual scientific claim, compare it with the best alternative explanation, and identify the relevant limitations.
Establish which experiment, clinical endpoint, customer outcome or operating metric would support or disprove the thesis.
Work backwards from meaningful adoption or clinical validation through staffing, regulation, manufacturing, capital and timelines.
Consider price, ownership, reserve needs, competition, commercial channels and the realistic range of outcomes.
Invest, collaborate, help form a company where justified, wait for more evidence, or pass. The correct answer is not always an investment.
Read all 5 stages as text
- Understand the mechanism. Reconstruct the actual scientific claim, compare it with the best alternative explanation, and identify the relevant limitations.
- Define the proof. Establish which experiment, clinical endpoint, customer outcome or operating metric would support or disprove the thesis.
- Build the development path. Work backwards from meaningful adoption or clinical validation through staffing, regulation, manufacturing, capital and timelines.
- Underwrite the company. Consider price, ownership, reserve needs, competition, commercial channels and the realistic range of outcomes.
- Decide what involvement adds. Invest, collaborate, help form a company where justified, wait for more evidence, or pass. The correct answer is not always an investment.
From laboratory judgment to investment judgment.
Laboratory work teaches you to be wary of a result that cannot be repeated. Equity research teaches you how quickly a good scientific narrative can become detached from price and expectations. Venture investing adds the longer question: can this team create enough evidence and enterprise value before it runs out of capital? Wytham Lane’s initial approach brings those perspectives together.
Capital has different shapes.
An early therapeutic, a diagnostics company, a software-enabled care service and an industrial asset should not be financed on identical assumptions. We are interested in building the capabilities and relationships to match each opportunity with an appropriate strategy. Any separate future vehicles or operating businesses would have their own governance and fiduciary responsibilities.
Boundaries matter.
Where an investment firm helps build companies, holds interests in operating businesses or collaborates with clinical providers, conflicts need to be disclosed and properly managed. Clinical decisions must remain subject to clinical standards; an attractive commercial relationship is not a substitute for independent evidence.
We want to be patient about the right things, demanding about the proof, and careful with the capital entrusted to us.